Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORTEC-3 endometrial cancer adjuvant chemoradiation trial
NL-OMON25773Phase 3Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2006
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin, carboplatin and paclitaxel in endometrial cancer (EC) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: 5-year actuarial overall survival and 5-year actuarial failure-free survival. Started Oct 2006; status: active, not recruiting.
02
Drugs
cisplatincarboplatinpaclitaxel
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON25773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25773.